Has Vrinda Hershberger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $39,305 in general payments to Vrinda Hershberger, MD across 117 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vrinda Hershberger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vrinda Hershberger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vrinda Hershberger, MD

Retina Specialist · Melbourne, FLNPI 1770574642

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,432 of the $39,305 with a category attached, or 64.7%. 19 manufacturers reported payments, led by Regeneron at 41.9% of the total. Reporting peaked in 2024 at $15,358 and has fallen 97.5% since, to $382 in 2025.

$39,305in general payments, 2019–2025

Across 117 payments — averaging $335.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron$16K
F. Hoffmann-la Roche AG$11K
Eyepoint US, Inc.$5K
Genentech, Inc.$3K
Roche TCRC, Inc.$1K
Regeneron Healthcare Solutions, Inc.$820
plus $2K from 13 others

$8,174,825in research payments, 2019–2025

Across 805 payments — averaging $10,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$3.8M
Roche TCRC, Inc.$1.6M
Bayer$994K
Eyepoint US, Inc.$773K
Regeneron$669K
AbbVie$111K
plus $220K from 5 others

What the payments were for

Consulting fees$25,43265%
Speaking & faculty fees$5,34914%
Travel & lodging$4,35811%
Food & beverage$4,16611%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron	22	$16,467
F. Hoffmann-la Roche AG	7	$11,374
Eyepoint US, Inc.	3	$4,674
Genentech, Inc.	14	$2,930
Roche TCRC, Inc.	3	$1,330
Regeneron Healthcare Solutions, Inc.	33	$820
Genentech USA, Inc.	10	$544
AbbVie	3	$228
Alcon	2	$166
Rxsight Inc	2	$153
Ocular Therapeutix, Inc.	2	$152
Astellas Pharma US Inc	5	$147
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$85
Amgen	3	$74
Notal Vision, Inc.	2	$50
Apellis Pharmaceuticals, Inc.	2	$43
Oyster Point Pharma, Inc.	1	$28
Harrow Eye, LLC	1	$26
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EYLEA HD$9,939
Non-Covered Product$9,254
EYLEA$6,255
EYP-1901$4,568
VABYSMO$364
RXSIGHT INJECTOR HANDPIECE$135
RXSIGHT CONTACT LENS$135
RXSIGHT INJECTOR CARTRIDGE$135
RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$135
RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
LUMIGAN$125
AcrySof IQ VIVITY IOL$121
Lucentis$111
YUTIQ$106

How this compares

$39,305 in reported general payments places this provider in the 85th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida →

Medicare billing

Part B allowed, 2024

$2,931,535

Medicare patients

707

Services billed

19,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Difluprednate	19	$2,787
Prednisolone Acetate	21	$879
ErythromycinErythromycin Base	21	$326

Paid to pharmacies, not to this prescriber.

Other retina specialist in Melbourne

Sunil GuptaPensacola$1.8M
Joseph NezgodaWest Palm Beach$600K
Eduardo UchiyamaFt Lauderdale$356K
Thomas AlbiniMiami$281K
Audina BerrocalMiami$210K
Philip RosenfeldMiami$206K
John MyersPensacola$152K
Timothy MurraySouth Miami$133K
Adiel SmithAventura$116K
Paul GalloglyPalm Beach Gardens$72K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →